SRR1381673
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.452
- KRAS_SIGNALING_DN+0.414
- COAGULATION+0.298
- BILE_ACID_METABOLISM+0.264
- XENOBIOTIC_METABOLISM+0.187
- ESTROGEN_RESPONSE_LATE+0.179
- MYOGENESIS+0.152
- APICAL_SURFACE+0.140
- ESTROGEN_RESPONSE_EARLY+0.119
- HEDGEHOG_SIGNALING+0.069
Top 10 suppressed
- MYC_TARGETS_V1-0.644
- PROTEIN_SECRETION-0.532
- UNFOLDED_PROTEIN_RESPONSE-0.530
- E2F_TARGETS-0.470
- MYC_TARGETS_V2-0.466
- MTORC1_SIGNALING-0.441
- G2M_CHECKPOINT-0.422
- DNA_REPAIR-0.403
- MITOTIC_SPINDLE-0.349
- ANDROGEN_RESPONSE-0.321
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1488651 | GTEX | — | 0.952 |
| 2 | SRR1472323 | GTEX | — | 0.950 |
| 3 | SRR1472663 | GTEX | — | 0.950 |
| 4 | SRR1479759 | GTEX | — | 0.945 |
| 5 | SRR1323174 | GTEX | — | 0.942 |
| 6 | TCGA-62-8397-01A-11R-2326-07 | — | cohortA1 | 0.939 |
| 7 | BS_912NX4Y0 | Ganglioglioma | — | 0.938 |
| 8 | SRR1330675 | GTEX | — | 0.938 |
| 9 | SRR1446287 | GTEX | — | 0.936 |
| 10 | SRR1382956 | GTEX | — | 0.936 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.452 | Cobimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.414 | Remibrutinib | — uncovered |
| COAGULATION | 0.298 | Binimetinib | — uncovered |
| BILE_ACID_METABOLISM | 0.264 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.187 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.179 | Idelalisib | — uncovered |
| MYOGENESIS | 0.152 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.140 | Temsirolimus | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.119 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.069 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.067 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.048 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.019 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.002 | Inavolisib | — uncovered |